Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 65 3-Year Revenue Growth Rate is 4.30% as of Jun. 2026, which is 78% below its 10-year median of 19.90. GuruFocus rates HMDCF with a GF Score™ of 65/100 and a GF Value™ of $2.25. The stock has 8 warning signs investors should review. Among 905 Drug Manufacturers companies, HUTCHMED (China) ranks better than 52.27% on this metric.
During the past 12 months, HUTCHMED (China)'s average Revenue per Share Growth Rate was -11.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 16.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of HUTCHMED (China) was 103.20% per year. The lowest was -42.00% per year. And the median was 19.90% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
HUTCHMED (China) 3-Year Revenue Growth Rate Related Terms
HMDCF vs ZTS, UTHR: 3-Year Revenue Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) 3-Year Revenue Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 4.30% mean?
HUTCHMED (China) (HMDCF) has a 3-Year Revenue Growth Rate of 4.30% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for HUTCHMED (China) and its competitors. This is 78% below median its historical median of 19.90. According to the industry distribution chart, HUTCHMED (China) ranks #432 out of 905 companies in the Drug Manufacturers industry, placing it in the top 47.7%.
Is HUTCHMED (China)'s 3-Year Revenue Growth Rate too high?
HUTCHMED (China)'s current 3-Year Revenue Growth Rate of 4.30% is 78% below median its 10-year median of 19.90. The Drug Manufacturers industry median 3-Year Revenue Growth Rate is 3.70. HUTCHMED (China)'s value of 4.30% is 16.2% above this industry median. Based on the distribution chart, HUTCHMED (China) ranks #432 out of 905 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, HUTCHMED (China) has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s 3-Year Revenue Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #432 out of 905 companies for 3-Year Revenue Growth Rate. This puts HUTCHMED (China) in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 3.70. HUTCHMED (China)'s value of 4.30% is 16.2% above this benchmark. While the company's 10-year median is 19.90 vs. the industry median of 3.70, HUTCHMED (China) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Drug Manufacturers company?
The median 3-Year Revenue Growth Rate among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current 3-Year Revenue Growth Rate of 4.30% is 16.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median 3-Year Revenue Growth Rate is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current 3-Year Revenue Growth Rate is 4.30%, which is 78% below median its own 10-year median of 19.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
HUTCHMED (China) (HMDCF) has a current 3-Year Revenue Growth Rate of 4.30%. The stock's GF Value™ is $2.25, compared to a current price of $2.16 — trading 4% below its estimated fair value. The current 3-Year Revenue Growth Rate is 4.30%, which is 78% below median its 10-year median of 19.90 and 16.2% above the Drug Manufacturers industry median of 3.70. HUTCHMED (China)'s overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current 3-Year Revenue Growth Rate is 4.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of $2.16 is trading 4% below its estimated GF Value™ of $2.25.
Key valuation signals for HMDCF:
3-Year Revenue Growth Rate: 4.30% (78% below median its 10-year median of 19.90)
GF Value™: $2.25 vs. price of $2.16 (4% below fair value)
Industry Position: 16.2% above the Drug Manufacturers median (#432 of 905)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
65GF Score
Get the complete analysis for HMDCF
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
